Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can magnetic pulses boost aging brains? new study seeks answers

NCT ID NCT07038798

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a non-invasive brain stimulation technique called deep transcranial magnetic stimulation (dTMS) is safe and tolerable for older adults with mild memory or thinking problems. Thirty participants aged 60-90 will receive one of three types of dTMS coils. Researchers will track side effects, thinking skills, brain activity, and mood to gather data for a future larger trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 60 - 90 years old * Able to provide informed consent to participate in the study * Subjective concern of mild decline in cognitive function over the past year * Mild impairment in cognitive performance * Preserved independence in everyday activities * Independently mobile (e.g., participants must be able to get in and out of a chair on their own) * Participants will be required to be on stable dosages of other psychotropic medications for at least 4 weeks prior to screening Exclusion Criteria: * Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder * Active suicidal behavior * Severe depression and/or anxiety * Other neurological or psychiatric disorders accounting for the cognitive deficits * Impairment in basic and/or instrumental activities of daily living * Substance use disorder (other than tobacco use disorder) in the past 3 months before entering the study * Traditional contraindications to rTMS: Intracranial or metal implants in the head or nearby regions, excluding the mouth, that cannot be safely removed; History of epilepsy or seizures; Active unstable medical condition (recent laboratory and neuroimaging alterations, delirium); Pacemaker and/or implantable cardioverter-defibrillators; current use of bupropion, treatment with equivalent benzodiazepine dose to lorazepam \>2 mg/day * People with severe literacy, visual, or hearing issues that affect the ability to engage in the interviews * People with recurring migraines or headaches (weekly or more) * Frequent dizziness/vertigo * Individuals residing beyond the borders of the Greater Hamilton Area and its neighbouring vicinities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild neurocognitive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton

    RECRUITING

    Hamilton, Ontario, L9C 0E3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.